ImCheck Announces First Patients Dosed in Phase II of EVICTION Trial for ICT01
| Science & Medicine
EVICTION trial proceeds to Phase IIa based on promising Phase I patient data for ICT01 across a broad range of solid…
For the third year in a row, ImCheck has been awarded by the French Tech as one of the top 120 French start-ups/scale-ups and among 7 French biotech developing innovative therapies
| Leadership & Corporate
ImCheck has been recognized again as one of the top 120 French start-ups and scale-ups based on performance…
ImCheck to Present at 40th Annual J.P. Morgan Healthcare Conference
| Science & Medicine
ImCheck Therapeutics announced today that its Chief Executive Officer, Pierre d’Epenoux, will present a corporate…
ImCheck Provides Promising Updated Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at SITC Meeting 2021
| Science & Medicine
Oral presentation includes positive safety data across a wide range of ICT01 doses and efficacy data from patients…
ImCheck Publishes Comprehensive Overview of the Development Results of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Gamma-delta T Cells in Science Translational Medicine
| Science & Medicine
- Publication underscores ImCheck’s pioneering role in Vγ9Vδ2 T cell-based immunotherapy capable of bridging to the…
ImCheck to Present Updated Patient Response Data from the EVICTION Trial and Additional ICT01 Results at the SITC Annual Meeting 2021
| Science & Medicine
ImCheck Therapeutics today announced that it will present updated clinical data from the ongoing EVICTION Phase I/IIa…
ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021
| Science & Medicine
First EVICTION data from checkpoint inhibitor-refractory solid tumor patients treated in the first two…
ImCheck to Present Early Patient Response Data from the EVICTION Trial at the ESMO Congress 2021
| Science & Medicine
ImCheck Therapeutics today announced that it will present updated clinical data from the ongoing EVICTION Phase I/IIa…
ImCheck Publishes Seminal Paper in Cell Reports Elucidating How Butyrophilins Activate Vγ9Vδ2 T cell Function Against Tumor Cells
| Science & Medicine
- First published study showing the role and sequential interaction of butyrophilin subtypes in the induction of…
ImCheck Announces Initiation of U.S. Enrollment in Phase I/IIa EVICTION Trial for ICT01
| Science & Medicine
EVICTION is a multi-center trial evaluating Butyrophilin 3A-targeted activation of the anti-tumor immune response of…
ImCheck Therapeutics Appoints Dr. Loui Madakamutil, Noted Expert in Immunology and Autoimmune Diseases, as Chief Scientific Officer
| Leadership & Corporate
ImCheck Therapeutics today announced the appointment of Loui Madakamutil, PhD, as Chief Scientific Officer (CSO). Dr.…
Clinical Data with ImCheck’s ICT01 to be Presented at AACR: Positive Results Observed on Safety, Activation of Gamma 9 Delta 2 T Cells and Anti-tumor Immune Response
| Science & Medicine
ICT01 activates γ9δ2 T cells that rapidly migrate out of the circulation and secrete IFNγ and TNFα leading to an…
ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting 2021
| Science & Medicine
ImCheck Therapeutics today announced that it will present clinical data from the ongoing EVICTION Phase I/IIa clinical…
For a second year, ImCheck has been selected by the French Tech as one of the top 120 French startups and of the 9 biotech companies developing innovative therapies
| Leadership & Corporate
Repeating its selection in 2020, ImCheck has again been recognized as one of the top 120 French startups based on…
ImCheck Presents at SITC First Clinical Demonstration of Gamma Delta T Cell Activation and Tumor Infiltration with Positive Safety for ICT01
| Science & Medicine
Preliminary EVICTION Phase I/IIa trial data shows butyrophilin-targeted mAb ICT01’s dose-dependent and specific…
ImCheck Announces Four ICT01 Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting
| Science & Medicine
Marseille, France, October 14, 2020 – ImCheck Therapeutics today announced the acceptance of four clinical and…
ImCheck Announces Investment by BB Pureos Bioventures to Close Series B Fundraising with Total of €54 million ($64 million)
| Financial & Business
ImCheck Therapeutics today announced that it has secured an additional €6 million ($7.1 million) from BB Pureos…
ImCheck Achieves Initial Positive Independent Safety Review and Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01 - Company Receives FDA Approval for US IND
| Science & Medicine
ImCheck Therapeutics announced today that the independent Safety Review Committee for the EVICTION Phase I/II clinical…
ImCheck Therapeutics Appoints Claude Knopf as Chief Business Officer
| Leadership & Corporate
First hire in the US will support growing global business development activities
Marseille, France, July 9, 2020 –…
HalioDx to Characterize the Immune Contexture of Patients Enrolled in ImCheck’s EVICTION Phase 1/2 Clinical Trial
| Science & Medicine